Three of the health secretary’s picks to replace fired members of an influential panel that sets U.S. vaccine policies have ...

The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC’s Advisory Committee on Immunization Practices on ...

Benchling announced a new collaboration with Merck, known as MSD outside of the United States and Canada, to implement a ...

During a Community Case Forum event, Adil Daud, MD, discussed immunotherapy options for cutaneous squamous cell carcinoma.

Among the eight people Robert F. Kennedy Jr. announced would make up his new group of outside vaccine advisers to the US ...

Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced ...

Merck (MRK) on Friday said that the U.S. Food and Drug Administration (FDA) has approved its blockbuster drug Keytruda for ...

Staff who provide data to the vaccine panel have been pushed aside, according to health officials, raising doubts about the ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...